Codon 72 Polymorphism and Various Human Papillomavirus 16 E 6 Genotypes Are Risk Factors for Cervical Cancer Development 1

Risk factors other than human papillomavirus (HPV) infection per se for cervical cancer development have been investigated recently. It was suggested that HPV 16 E6 variants and the p53 codon 72 arginine polymorphism could be progression markers. Indeed, it has been demonstrated that specific E6 variants and p53 arginine were both enriched in cancer. However, especially with regard to the latter, divergent results have been reported. Our aim was thus to investigate whether p53 arginine is important for cervical carcinogenesis by scaling up samples of the two European cohorts, the initial results of which were reported previously. In addition, we have assessed the occurrence of p53 codon 72 arginine, in combination with specific HPV 16 E6 genotypes. We found p53 arginine to be increased in cancer of both cohorts, consistent with our previous concept. Although specificE6 genotypes increased gradually with the severity of the lesion, p53 arginine was enriched in cancer only. Moreover, the frequency of the arginine allele was similar in groups with differentE6 genotypes. It is concluded that p53 arginine is a risk factor for cervical cancer but probably acts independently of E6 variants.

[1]  Ranajit Chakraborty,et al.  p53 codon 72 polymorphism and risk of cervical cancer. , 2003, Biological research.

[2]  E. Franco,et al.  p53 polymorphism in codon 72 and risk of human papillomavirus‐induced cervical cancer: effect of inter‐laboratory variation , 2000, International journal of cancer.

[3]  T. Agorastos,et al.  p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women. , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[4]  C. Meijer,et al.  Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. , 2000, The Journal of general virology.

[5]  G. Voglino,et al.  Codon 72 polymorphism of p53 and its association with cervical cancer , 1999, The Lancet.

[6]  M. von Knebel Doeberitz,et al.  No evidence of p53 allele-specific predisposition in human papillomavirus-associated cervical cancer , 1999, Journal of Molecular Medicine.

[7]  Patrik K. E. Magnusson,et al.  p53 polymorphism and risk of cervical cancer , 1998, Nature.

[8]  H. Hollema,et al.  Homozygous arginine-72 in wild type p53 and risk of cervical cancer , 1998, The Lancet.

[9]  R. Gornall,et al.  p53 polymorphism and risk of cervical cancer , 1998, The Lancet.

[10]  G. Voglino,et al.  Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms , 1998, The Lancet.

[11]  Y. Nakamura,et al.  No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. , 1998, Cancer research.

[12]  I. Jacobs,et al.  p53 codon 72 polymorphism and risk of cervical cancer in UK , 1998, The Lancet.

[13]  Irene M. Leigh,et al.  Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.

[14]  E. Wilander,et al.  Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. , 1998, Cancer research.

[15]  C. Wheeler,et al.  Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective , 1997, Journal of virology.

[16]  J. Cuzick,et al.  Human papillomavirus genotype as a predictor of persistence and development of high‐grade lesions in women with minor cervical abnormalities , 1996, International journal of cancer.

[17]  R. Birgander,et al.  Is p53 polymorphism maintained by natural selection? , 1994, Human heredity.

[18]  H. Hausen Human papillomaviruses in the pathogenesis of anogenital cancer. , 1991 .

[19]  S. Suhai,et al.  Human papillomavirus type 16 DNA sequence. , 1985, Virology.

[20]  D. Mayer,et al.  Biochemical microanalysis of glycogen content and glucose-6-phosphate dehydrogenase activity in focal lesions of the rat liver induced by N-nitrosomorpholine. , 1984, Carcinogenesis.